Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma. Transplant Cell Ther 2026 Oct;32(10):1350.e1-1350.e11

Date

05/23/2026

Pubmed ID

42173253

Pubmed Central ID

PMC13405239

DOI

10.1016/j.jtct.2026.05.030

Scopus ID

2-s2.0-105043126201 (requires institutional sign-in at Scopus site)

Abstract

Plasmablastic lymphoma (PBL) is a rare and aggressive type of non-Hodgkin lymphoma with biological features that overlap between B-cell lymphoma and plasma cell neoplasm. There is currently no established standard treatment. However, intensive combination regimens, such as EPOCH, are recommended. There is a paucity of data regarding outcomes of hematopoietic cell transplantation (HCT) in this disease. Herein, we analyze data of patients with PBL who received autologous (autoHCT) or allogeneic (alloHCT) transplants using the Center for International Marrow and Transplant Research (CIBMTR) Registry. Between 2015 and 2024, a total of 186 and 31 patients underwent autoHCT and alloHCT, respectively, and met eligibility for the study. In the autoHCT group, 3-year overall survival (OS) was 75.5% (95% confidence interval [CI]: 68.3%-82.1%] and 3-year PFS was 60.6% (95% CI: 52.4%-68.5%], whereas 3-year NRM was 6.2% (95% CI: 2.9%-10.6%]. Outcomes of patients who received autoHCT after only 1 line of therapy were significantly better, with 3-year progression-free survival (PFS) at 74.7% (95% CI: 61%-85.7%] compared with 54% (95% CI: 39.9%-67.8%) in patients who received more than 1 line of therapy prior to transplantation (P = .046). In the alloHCT group, 3-year OS was 37.2% (95% CI: 19%-57.5%), 3-year PFS was 33.3% (95% CI: 16.3%-53.3%), and 3-year graft-versus-host disease-free/relapse-free survival was 20.8% (95% CI: 7.9%-37.8%), whereas 3-year nonrelapse mortality was 23.3% (95% CI: 8%-43.5%) and 3-year relapse risk was 43.3% (95% CI: 26%-61.6%). Relapse risk appears to plateau at approximately 1 year, suggesting the potential for curative outcomes in this disease. Overall, both autoHCT and alloHCT have demonstrated the potential to achieve prolonged survival in this aggressive lymphoma. However, early implementation of autoHCT following first-line therapy was associated with the most favorable outcomes.

Author List

Al-Juhaishi T, Ahn KW, Chen T, Patel KK, Patel J, Herrera AF, Turtle CJ, Rizzo JD, Khimani F, Awan FT, Gibran-Nunes F, Ahmed G, Baird J, Lekakis LJ, Shadman M, Shafey M, Reidell PA, Merryman RW, Hamadani M, Ahmed S

Authors

Kwang Woo Ahn PhD Director, Professor in the Data Science Institute department at Medical College of Wisconsin
Mehdi Hamadani MBBS Professor in the Medicine department at Medical College of Wisconsin
Jinal K. Patel Biostatistician II in the Center for International Blood and Marrow Transplant Research department at Medical College of Wisconsin
J. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Plasmablastic Lymphoma
Transplantation, Autologous
Transplantation, Homologous
Treatment Outcome
Young Adult